Bristol-Myers Squibb’s acquisition of Celgene may generate a significant tax burden for Celgene stockholders.
Join our 30 minute webinar
- Examples of taxability for Celgene shareholders
- Update on strategies to reduce taxes
- What you can do to prepare as an employee
- How Celgene stock options will be impacted
This session is not a substitute for personalized advice from RegentAtlantic. Please be sure to consult with your tax or legal advisors.